Beth A. Hellerstedt

2.0k total citations
32 papers, 1.0k citations indexed

About

Beth A. Hellerstedt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Beth A. Hellerstedt has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Beth A. Hellerstedt's work include HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Beth A. Hellerstedt is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Beth A. Hellerstedt collaborates with scholars based in United States, France and Italy. Beth A. Hellerstedt's co-authors include Joyce O’Shaughnessy, Frankie A. Holmes, John Pippen, W. Fraser Symmans, Kenneth J. Pienta, Lajos Pusztai, Daniel J. Booser, Yuan Qi, Gabriel N. Hortobágyi and Libero Santarpia and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Beth A. Hellerstedt

32 papers receiving 986 citations

Peers

Beth A. Hellerstedt
J.P. Delord France
Vali Papadimitrakopoulou United States
Ladan Fazlollahi United States
Amélie Boichard United States
Vijay Peddareddigari United States
Joseph J. Stephenson United States
Huiying Piao United States
H Sawada Japan
Hiroshi Haeno Japan
Alexander C. Klimowicz Canada
J.P. Delord France
Beth A. Hellerstedt
Citations per year, relative to Beth A. Hellerstedt Beth A. Hellerstedt (= 1×) peers J.P. Delord

Countries citing papers authored by Beth A. Hellerstedt

Since Specialization
Citations

This map shows the geographic impact of Beth A. Hellerstedt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth A. Hellerstedt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth A. Hellerstedt more than expected).

Fields of papers citing papers by Beth A. Hellerstedt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth A. Hellerstedt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth A. Hellerstedt. The network helps show where Beth A. Hellerstedt may publish in the future.

Co-authorship network of co-authors of Beth A. Hellerstedt

This figure shows the co-authorship network connecting the top 25 collaborators of Beth A. Hellerstedt. A scholar is included among the top collaborators of Beth A. Hellerstedt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth A. Hellerstedt. Beth A. Hellerstedt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hellerstedt, Beth A., Nicholas J. Vogelzang, Harriet M. Kluger, et al.. (2018). Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma. Clinical Lung Cancer. 20(2). 74–81.e1. 18 indexed citations
2.
3.
Yardley, Denise A., Sara A. Hurvitz, Masakazu Toi, et al.. (2017). Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1. Cancer Research. 77(4_Supplement). P4–22. 3 indexed citations
4.
Hellerstedt, Beth A., Steven W. Papish, Regina Resta, et al.. (2016). Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole. Journal of Clinical Oncology. 34(14). 1594–1600. 15 indexed citations
5.
Piha‐Paul, Sarina A., James A. Knost, Fadi S. Braiteh, et al.. (2015). Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.. Journal of Clinical Oncology. 33(15_suppl). 2516–2516. 3 indexed citations
6.
Sonpavde, Guru, C. Lance Cowey, Beth A. Hellerstedt, et al.. (2012). Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community. Clinical Genitourinary Cancer. 10(1). 1–5. 43 indexed citations
7.
Sharman, Jeff P., Jerome H. Goldschmidt, John M. Burke, et al.. (2012). CD30 expression in nonlymphomatous malignancies.. Journal of Clinical Oncology. 30(15_suppl). 3069–3069. 10 indexed citations
8.
Santarpia, Libero, Yuan Qi, Katherine Stemke‐Hale, et al.. (2012). Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment. 134(1). 333–343. 94 indexed citations
9.
Galsky, Matthew D., Noah M. Hahn, Thomas Powles, et al.. (2012). Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 11(2). 175–181. 69 indexed citations
10.
Han, Xiang Y., Beth A. Hellerstedt, & Charles Koller. (2010). Postsplenectomy Cytomegalovirus Mononucleosis is a Distinct Clinicopathologic Syndrome. The American Journal of the Medical Sciences. 339(4). 395–399. 13 indexed citations
11.
Iwamoto, Takayuki, Giampaolo Bianchini, Daniel J. Booser, et al.. (2010). Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. JNCI Journal of the National Cancer Institute. 103(3). 264–272. 179 indexed citations
12.
Wenstrup, Richard, Beth A. Hellerstedt, Julia Reid, et al.. (2010). Hereditary breast and ovarian cancer testing: integration and outcomes within community oncology practices. Community Oncology. 7(2). 75–81. 2 indexed citations
13.
Dunn, Rodney L., Beth A. Hellerstedt, Kathleen A. Cooney, et al.. (2006). Dose escalation of oral vinorelbine in combination with estramustine in hormone‐refractory adenocarcinoma of the prostate. Cancer. 106(12). 2617–2623. 2 indexed citations
14.
Hellerstedt, Beth A. & Kenneth J. Pienta. (2003). The truth is out there: an overall perspective on androgen deprivation. Urologic Oncology Seminars and Original Investigations. 21(4). 272–281. 10 indexed citations
15.
16.
Hellerstedt, Beth A., Kenneth J. Pienta, Bruce G. Redman, et al.. (2003). Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma. Cancer. 98(8). 1603–1610. 28 indexed citations
17.
Hellerstedt, Beth A. & Kenneth J. Pienta. (2003). Germ cell tumors: review of selected studies from 2002. Current Opinion in Oncology. 15(3). 234–238. 7 indexed citations
18.
Yanik, Gregory A., Beth A. Hellerstedt, Joseph R. Custer, et al.. (2002). Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 8(7). 395–400. 92 indexed citations
19.
Chay, Christopher H., et al.. (2002). Antimetastatic Drugs in Prostate Cancer. PubMed. 1(1). 14–19. 7 indexed citations
20.
Hellerstedt, Beth A. & Kenneth J. Pienta. (2002). Testicular cancer. Current Opinion in Oncology. 14(3). 260–264. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.P. Delord Breakdown of academic impact, for papers by Vali Papadimitrakopoulou Breakdown of academic impact, for papers by Ladan Fazlollahi Breakdown of academic impact, for papers by Amélie Boichard Breakdown of academic impact, for papers by Vijay Peddareddigari Breakdown of academic impact, for papers by Joseph J. Stephenson Breakdown of academic impact, for papers by Huiying Piao Breakdown of academic impact, for papers by H Sawada Breakdown of academic impact, for papers by Hiroshi Haeno Breakdown of academic impact, for papers by Alexander C. Klimowicz
Rankless by CCL
2026